Silencing of the COPS3 Gene by siRNA Reduces Proliferation of Lung Cancer Cells Most Likely via induction of Cell Cycle Arrest and Apoptosis |
Wang, Xue-Mei
(Cancer Center, the First Hospital of Jilin University)
Cui, Jiu-Wei (Cancer Center, the First Hospital of Jilin University) Li, Wei (Cancer Center, the First Hospital of Jilin University) Cai, Lu (Cancer Center, the First Hospital of Jilin University) Song, Wei (Cancer Center, the First Hospital of Jilin University) Wang, Guan-Jun (Cancer Center, the First Hospital of Jilin University) |
1 | Bech-Otschir D, Kraft R, Huang X, et al (2001). COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J, 20, 1630-9. DOI ScienceOn |
2 | Broker LE, Giaccone G (2002). The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer, 38, 2347-61. DOI |
3 | Chen L, Liang Z, Tian Q, et al (2011). Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC. J Exp Clin Cancer Res, 30, 18. DOI |
4 | Devi G R (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther, 13, 819-29. DOI ScienceOn |
5 | Fuchs B, Pritchard DJ (2002). Etiology of osteosarcoma. Clin Orthop, 397, 40-52. DOI |
6 | Gokgoz N, Wunder JS, Mousses S, et al (2001). Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer, 92, 2181-9. DOI |
7 | Henriksen J, Aagesen TH, Maelandsmo GM, et al (2003). Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasomemediated degradation. Oncogene, 22, 5358-61. DOI |
8 | Luo J, Emanuele MJ, Li D, et al (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 137, 835-48. DOI |
9 | Paddison PJ, Hannon GJ (2003). siRNAs and shRNAs: skeleton keys to the human genome. Curr Opin Mol Ther, 5, 217-24. |
10 | Sharma SV, Bell DW, Settleman J, Haber DA (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, 169-81. DOI ScienceOn |
11 | Singh A, Boldin-Adamsky S, Thimmulappa RK, et al (2008). RNAi-mediated silencing of nuclear factor erythroid-2- related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res, 68, 7975-84. DOI |
12 | Skrzypski M, Dziadziuszko R, Jassem J (2011). MicroRNA in lung cancer diagnostics and treatment. Mutat Res, 17, 25-31. |
13 | van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJ (2004). Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in highgrade osteosarcoma. Cancer Genet Cytogenet, 152, 8-14. DOI |
14 | Wei N, Deng XW (2003). The COP9 signalosome. Annu Rev Cell Dev Biol, 19, 261-86. DOI |
15 | Yan J, Walz K, Nakamura H, et al (2003). COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. Mol Cell Biol, 23, 6798-808. DOI |
16 | Yan T, Wunder JS, Gokgoz N, et al (2007). COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 109, 1870-6. DOI |
17 | Yan T, Tang G, Ren T, et al (2011). RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther, 18, 450-6. DOI |